Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug YL201 enters human trials for Hard-to-Treat cancers

NCT ID NCT05434234

Recruiting now Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every three weeks, sometimes combined with another cancer drug called atezolizumab. The goal is to see if it is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

YL201 (a drug given by IV infusion every 3 weeks, alone or with atezolizumab)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.

What could go wrong

This is an early, first-in-human study, so safety and effectiveness are not yet known. The drug may cause side effects or not shrink tumors as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 001

    RECRUITING

    La Jolla, California, 92093-0698, United States

    Contact

  • 002

    RECRUITING

    Fair Oaks, California, 95628, United States

    Contact

  • 003

    RECRUITING

    Lone Tree, Colorado, 80124, United States

    Contact

  • 004

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact

  • 005

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • 006

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact

  • 007

    RECRUITING

    Detroit, Michigan, 48292, United States

    Contact

  • 008

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

  • 009

    RECRUITING

    Santa Fe, New Mexico, 87505-699, United States

    Contact

  • 010

    RECRUITING

    New York, New York, 10029, United States

    Contact

  • 011

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

    Contact

  • 012

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

  • 013

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

  • 014

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

  • 015

    RECRUITING

    Irving, Texas, 75039, United States

    Contact

  • 016

    RECRUITING

    Tyler, Texas, 75701, United States

    Contact

  • 017

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

  • 018

    RECRUITING

    Spokane, Washington, 99208, United States

    Contact

  • 019

    RECRUITING

    Tacoma, Washington, 98405, United States

    Contact

  • 020

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

    Contact

  • 021

    RECRUITING

    Kelowna, British Columbia, V1Y 1E2, Canada

    Contact

  • 022

    RECRUITING

    Brampton, Ontario, L6R 3J7, Canada

    Contact

  • 023

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

    Contact

  • 024

    COMPLETED

    Guangzhou, Guangdong, 510000, China

  • 025

    COMPLETED

    Zhengzhou, Henan, 450003, China

  • 026

    RECRUITING

    Bordeaux, 33000, France

    Contact

  • 027

    RECRUITING

    Dijon, 21000, France

    Contact

  • 028

    RECRUITING

    Marseille, 13005, France

    Contact

  • 029

    NOT_YET_RECRUITING

    Nantes, 44093, France

    Contact

  • 030

    NOT_YET_RECRUITING

    Paris, 75248, France

    Contact

  • 031

    RECRUITING

    Poitiers, 86021, France

    Contact

  • 032

    NOT_YET_RECRUITING

    Saint-Herblain, 44800, France

    Contact

  • 033

    RECRUITING

    Suresnes, 92150, France

    Contact

  • 034

    RECRUITING

    Barcelona, Barcelona, 08023, Spain

    Contact

  • 035

    RECRUITING

    Barcelona, Barcelona, 08025, Spain

    Contact

  • 036

    RECRUITING

    Madrid, Madrid, 28050, Spain

    Contact

  • 037

    RECRUITING

    Madrid, Madrid, 28034, Spain

    Contact

  • 038

    RECRUITING

    Moncloa-Aravaca, Madrid, 28040, Spain

    Contact

  • 039

    NOT_YET_RECRUITING

    Leganés, Madrid, 28911, Spain

    Contact

  • 040

    RECRUITING

    Pamplona, Navarre, 31008, Spain

    Contact

  • 041

    RECRUITING

    Pozuelo de Alarcón, Madrid, 28223, Spain

    Contact

  • 042

    RECRUITING

    Usera, Madrid, 28041, Spain

    Contact

  • 043

    RECRUITING

    Valencia, Valencia, 46010, Spain

    Contact

  • 044

    RECRUITING

    Otwock, 05-400, Poland

    Contact

  • 045

    NOT_YET_RECRUITING

    Poznan, 60-569, Poland

    Contact